Navigation Links
Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
Date:11/18/2013

II is an important regulator of triglycerides in the blood.  As such, a drug targeted to reduce ApoC-III should have a profound and positive effect on triglyceride levels," said John Kastelein, M.D., Ph.D., professor of medicine, chairman of the department of vascular medicine, Academic Medical Center, University of Amsterdam.  "ISIS-APOCIIIRx has been shown to be a robust triglyceride-lowering agent in patients with moderately high to severely high triglycerides in multiple Phase 2 settings.  Based on the comprehensive Phase 2 data for ISIS-APOCIIIRx, I am very encouraged about the therapeutic potential for ISIS-APOCIIIRx in patients with severely high triglycerides, especially for use in FCS patients who have extremely high triglyceride levels and very limited therapeutic options."

The monotherapy portion of the Phase 2 study of ISIS-APOCIIIRx is a double-blind, randomized, placebo-controlled 13-week study designed to assess the safety and activity of ISIS-APOCIIIRx in patients with very high to severely high triglyceride levels (between 440 and 2,000 mg/dL).  In this study, patients received 100 mg, 200 mg or 300 mg dose of ISIS-APOCIIIRx, or placebo via weekly subcutaneous injections for 13 weeks.  Patients treated with 300 mg ISIS-APOCIIIRx experienced dose-dependent, robust, prolonged and statistically significant mean reductions in apoC-III, triglycerides and apoC-III-associated VLDL particles of 80, 71 and 88 percent from baseline, respectively.  Furthermore, these patients demonstrated a statistically significant mean increase of 46 percent from baseline in HDL-C.  In this study ISIS-APOCIIIRx was found to be generally safe and well tolerated.  The most common adverse event (AE) was injection site reactions, which were infrequent, predominantly mild and typically resolved rapidly.  There wer
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
(Date:8/3/2015)... and MINNEAPOLIS , ... BSX ) has become a significant shareholder and ... representative for Preventice Solutions for cardiology-related diagnostic and ... an important strategic milestone for Preventice Solutions," said ... Strategy Officer, co CEO, Preventice Solutions.  "We are ...
(Date:8/3/2015)... 3, 2015 Diplomat Pharmacy, Inc. (NYSE: DPLO ... for the quarter ended June 30, 2015. All comparisons, unless ... Second Quarter 2015 Highlights include: ... $266 million , Total prescriptions dispensed of 234,000, an ... 5.5% , Adjusted EBITDA of $22.7 million, an increase ...
Breaking Medicine Technology:Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2Boston Scientific Announces Equity Investment And Sales Cooperation Agreement With Preventice Solutions 2Diplomat Announces 2nd Quarter 2015 Financial Results 2Diplomat Announces 2nd Quarter 2015 Financial Results 3Diplomat Announces 2nd Quarter 2015 Financial Results 4Diplomat Announces 2nd Quarter 2015 Financial Results 5Diplomat Announces 2nd Quarter 2015 Financial Results 6Diplomat Announces 2nd Quarter 2015 Financial Results 7Diplomat Announces 2nd Quarter 2015 Financial Results 8Diplomat Announces 2nd Quarter 2015 Financial Results 9Diplomat Announces 2nd Quarter 2015 Financial Results 10Diplomat Announces 2nd Quarter 2015 Financial Results 11Diplomat Announces 2nd Quarter 2015 Financial Results 12Diplomat Announces 2nd Quarter 2015 Financial Results 13Diplomat Announces 2nd Quarter 2015 Financial Results 14Diplomat Announces 2nd Quarter 2015 Financial Results 15Diplomat Announces 2nd Quarter 2015 Financial Results 16Diplomat Announces 2nd Quarter 2015 Financial Results 17Diplomat Announces 2nd Quarter 2015 Financial Results 18
... Jennerex,Inc. (San Francisco, CA and Ottawa, Ontario), and ... of the first five patients in a,Phase 2 primary ... JX-594. No significant toxicities were reported, and enrollment of,patients ... The Phase 2 trial involves treatment of patients ...
... Pulmo BioTech Inc. has completed a dual listing. The ... (symbol PBO) in addition to the OTC BB (OTC ... role in the future development and financing of the ... the United States and Canada" - Garry McCann, CEO ...
Cached Medicine Technology:Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 2Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 3Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer 4Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 2Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... analysis for executives and technology professionals in healthcare and technology markets, today announced ... the Department of Defense’s recently-announced Electronic Health Record (EHR) decision. The DOD related ...
(Date:8/3/2015)... ... August 04, 2015 , ... Approved ... extensive line up of live courses for the month of August. , Physical ... individually or by purchasing a Physical Therapy Flex package. Flex packages allow ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Putnam counties. As a family owned and operated business, Zeiter’s Septic has ... They are a leader in septic installations because of their continued training and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Since 1978, the number ... according to a new publication released today by the AAMC (Association of American Medical ... graduates over the past three decades, the number of black male applicants to medical ...
(Date:8/3/2015)... ... ... According to an opinion piece published July 28 by the Washington Post, the ... weight loss may not be accurate. While this system may work for some people, the ... – based both on the individual and at what point that person is in their ...
Breaking Medicine News(10 mins):Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 2Health News:Elite Online CE Provider Announces Schedule of Live Courses For Florida Physical Therapy Continuing Education 3Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 2Health News:Zeiter’s Septics Performs Affordable Septic Installations Throughout Livingston & Putnam Counties Effective Immediately 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2
... of Internal Medicine journal, Obese or overweight Chinese individuals ... developing tuberculosis than those at a normal weight. ... undernutrition in both developed and developing countries. In addition, ... a wide range of chronic degenerative conditions, notably, diabetes ...
... University of Washington shows that the work intended for ... economy . ,The research was conducted by a ... Hagopian, professor in the School of Public Health and ... Initiative; and Sally Weatherford, finance and administration director of ...
... guitarist Kevin Eubanks have won the 'World's Sexiest Vegetarians' title at ... new to the title, for she won the tag in 2005 ... for NBC's 'Tonight Show' band leader Eubanks, who bagged votes due ... for the 49-year-old and 'bring honour' to the show. ...
... researchers identify cost-effective treatment for drug-resistant typhoid. Researchers ... may be more effective at treating typhoid fever ... Organisation. ,Enteric fever, of which typhoid fever ... affecting the developing world, where sanitary conditions remain poor. ...
... have found that umbilical cord blood might safely preserve insulin ... ,The study was conducted by a team of ... Florida. ,As part of the study, researchers identified ... their umbilical cord blood at birth, and gave seven patients ...
... study published in the Journal of the National Cancer ... cancers is increasing, but this finding is likely ... Deirdre Cronin-Fenton, Ph.D., of Aarhus University Hospital in Denmark, ... Md., found that the increase in some early stage ...
Cached Medicine News:Health News:Obesity is Related to Lower Tuberculosis Risk 2Health News:Global Health Enriching the States Economy 2Health News:Gatifloxacin Very Effective for Typhoid Treatment 2
... ring pessary, available in nine ... support, is a very common ... second degree prolapse. The Ring ... used on an accompanying cystocele. ...
The Capio CL Transvaginal Suture Capturing Device allows for a transvaginal suture fixation to Cooper's Ligament for sling procedures...
... SPARC™ Sling System utilizes a suprapubic ... incontinence due to urethral hypermobility and/or ... two curved, narrow-diameter needles and a ... suture that allows for intra-operative tension ...
... technology marries with the well-researched ... sling, for exceptional resultsby design. ... and host, reduces the potential ... or erosion and provides secure ...
Medicine Products: